CVRX Stock Overview
A commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CVRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.52 |
| 52 Week High | US$33.14 |
| 52 Week Low | US$6.40 |
| Beta | 1.22 |
| 11 Month Change | 0.24% |
| 3 Month Change | -11.53% |
| 1 Year Change | -45.63% |
| 33 Year Change | -54.73% |
| 5 Year Change | n/a |
| Change since IPO | -69.57% |
Recent News & Updates
Recent updates
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Jul 31
Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Jun 18The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
May 04Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt
Apr 10The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%
Feb 29Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%
Nov 11Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth
Aug 20CVRx Pursues Revenue Growth But Operating Losses Worsen
Aug 05CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales
Jun 21We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth
Apr 12Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33
Feb 18CVRx: The Path To 7x Investment Returns
Jan 07CVRx: High Risk And High Potential Reward
Jul 04Shareholder Returns
| CVRX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -13.6% | -1.3% | -2.7% |
| 1Y | -45.6% | 14.0% | 21.3% |
Return vs Industry: CVRX underperformed the US Medical Equipment industry which returned 12.7% over the past year.
Return vs Market: CVRX underperformed the US Market which returned 21.1% over the past year.
Price Volatility
| CVRX volatility | |
|---|---|
| CVRX Average Weekly Movement | 16.3% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CVRX's share price has been volatile over the past 3 months.
Volatility Over Time: CVRX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 200 | Kevin Hykes | www.cvrx.com |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally.
CVRx, Inc. Fundamentals Summary
| CVRX fundamental statistics | |
|---|---|
| Market cap | US$192.80m |
| Earnings (TTM) | -US$54.39m |
| Revenue (TTM) | US$44.39m |
4.2x
P/S Ratio-3.4x
P/E RatioIs CVRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVRX income statement (TTM) | |
|---|---|
| Revenue | US$44.39m |
| Cost of Revenue | US$6.93m |
| Gross Profit | US$37.47m |
| Other Expenses | US$91.86m |
| Earnings | -US$54.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | 84.40% |
| Net Profit Margin | -122.52% |
| Debt/Equity Ratio | 53.1% |
How did CVRX perform over the long term?
See historical performance and comparison